PABA treatment may protect retinal function and attenuate the course of retinal degeneration in rd10 mice. Biochemical parameters indicate a lower degree of oxidative injury in PABA-treated retinas. PABA may potentially serve as an addition to antioxidative treatment for retinal and macular degenerations.

Purpose: To estimate the corneal measurements using Scheimpflug camera in patients with diabetes mellitus.Methods: Twenty five diabetic patients were prospectively recruited. Two groups were stratified, diabetic group and control group. Central corneal thickness (CCT), keratometry values (Kmean and Kmax), corneal volume (CV), anterior chamber depth (ACD), anterior chamber volume (ACV), Qvalue, frontal and back elevation, and the parameters of corneal variance indices, including minimum radius (Rmin) were measured using Pentacam Scheimpflug camera. Endothelial cell density (ECD) was also recorded. Findings were evaluated and compared between the 2 groups.Results: Two groups were found to have different Kmax (P = 0.03, one-tailed) and Rmin (P = 0.04, one-tailed) parameters. There was no statistical significant difference between the 2 groups in CCT, Kmean, CV, ACD, ACV, frontal/back elevation, Qvalue, ECD, and parameters of corneal variance indices.Conclusions: Diabetes mellitus affects keratometry and radius values of the human cornea based on the corneal measurements from Scheimpflug camera.

Poor initial VA should not prevent use of bevacizumab in eyes with NVAMD. Selection of patients with signs of active neovascularisation based on ophthalmoscopy, OCT and FA may increase the likelihood of a favourable response to treatment.

There is a trend to reduced incidence of early post-vitrectomy hemorrhage in patients undergoing vitrectomy for complications of proliferative diabetic retinopathy that have been pre-treated with intravitreal bevacizumab 1 week prior to surgery.